Literature DB >> 27417711

(1)H-MRS and MEGA-PRESS pulse sequence in the study of balance of inhibitory and excitatory neurotransmitters in the human brain of ultra-high risk of schizophrenia patients.

P E Menschikov1, N A Semenova2,3,4, M V Ublinskiy2,3, T A Akhadov3, R A Keshishyan3, I S Lebedeva5, M A Omelchenko5, V G Kaleda5, S D Varfolomeev2.   

Abstract

The MEGA-PRESS pulse sequence was used for determination of overlapping signals in the (1)H-MRS spectra of the human brain. For the first time, the balance of GABA glutamate/glutamine concentrations was estimated quantitatively in the human brain of patients with ultra-high risk of schizophrenia. It was found that GABA concentration and GABA/GLX ratios were significantly reduced in the left frontal lobe of UHR subjects.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27417711     DOI： 10.1134/S1607672916030029

Source DB:  PubMed          Journal:  Dokl Biochem Biophys        ISSN： 1607-6729            Impact factor:   0.788


  14 in total

1.  Testing the glutamate hypothesis of schizophrenia.

Authors:  Joshua A Gordon
Journal:  Nat Neurosci       Date:  2010-01       Impact factor: 24.884

2.  Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy.

Authors:  Lawrence S Kegeles; Xiangling Mao; Arielle D Stanford; Ragy Girgis; Najate Ojeil; Xiaoyan Xu; Roberto Gil; Mark Slifstein; Anissa Abi-Dargham; Sarah H Lisanby; Dikoma C Shungu
Journal:  Arch Gen Psychiatry       Date:  2012-01-02

3.  Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins.

Authors:  Clare L Beasley; Zhi J Zhang; Iain Patten; Gavin P Reynolds
Journal:  Biol Psychiatry       Date:  2002-10-01       Impact factor: 13.382

4.  GABA concentration is reduced in visual cortex in schizophrenia and correlates with orientation-specific surround suppression.

Authors:  Jong H Yoon; Richard J Maddock; Ariel Rokem; Michael A Silver; Michael J Minzenberg; J Daniel Ragland; Cameron S Carter
Journal:  J Neurosci       Date:  2010-03-10       Impact factor: 6.167

5.  Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia.

Authors:  Alice Egerton; Stefan Brugger; Marie Raffin; Gareth J Barker; David J Lythgoe; Philip K McGuire; James M Stone
Journal:  Neuropsychopharmacology       Date:  2012-07-04       Impact factor: 7.853

6.  Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics.

Authors:  S Akbarian; J J Kim; S G Potkin; J O Hagman; A Tafazzoli; W E Bunney; E G Jones
Journal:  Arch Gen Psychiatry       Date:  1995-04

Review 7.  Current practice in the use of MEGA-PRESS spectroscopy for the detection of GABA.

Authors:  Paul G Mullins; David J McGonigle; Ruth L O'Gorman; Nicolaas A J Puts; Rishma Vidyasagar; C John Evans; Richard A E Edden
Journal:  Neuroimage       Date:  2012-12-13       Impact factor: 6.556

8.  Simultaneous in vivo spectral editing and water suppression.

Authors:  M Mescher; H Merkle; J Kirsch; M Garwood; R Gruetter
Journal:  NMR Biomed       Date:  1998-10       Impact factor: 4.044

Review 9.  The neurobiology and treatment of first-episode schizophrenia.

Authors:  R S Kahn; I E Sommer
Journal:  Mol Psychiatry       Date:  2014-07-22       Impact factor: 15.992

10.  GABA and glutamate in schizophrenia: a 7 T ¹H-MRS study.

Authors:  Anouk Marsman; René C W Mandl; Dennis W J Klomp; Marc M Bohlken; Vincent O Boer; Anna Andreychenko; Wiepke Cahn; René S Kahn; Peter R Luijten; Hilleke E Hulshoff Pol
Journal:  Neuroimage Clin       Date:  2014-10-15       Impact factor: 4.881
View more
  7 in total

1.  Dopamine and glutamate in individuals at high risk for psychosis: a meta-analysis of in vivo imaging findings and their variability compared to controls.

Authors:  Robert A McCutcheon; Kate Merritt; Oliver D Howes
Journal:  World Psychiatry       Date:  2021-10       Impact factor: 79.683

2.  Inhibitory motor dysfunction in parkinson's disease subtypes.

Authors:  Tao Gong; Yuanyuan Xiang; Muhammad G Saleh; Fei Gao; Weibo Chen; Richard A E Edden; Guangbin Wang
Journal:  J Magn Reson Imaging       Date:  2017-09-27       Impact factor: 4.813

Review 3.  Neuroimaging studies of GABA in schizophrenia: a systematic review with meta-analysis.

Authors:  A Egerton; G Modinos; D Ferrera; P McGuire
Journal:  Transl Psychiatry       Date:  2017-06-06       Impact factor: 6.222

4.  Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms.

Authors:  Gemma Modinos; Fatma Simsek; Jamie Horder; Matthijs Bossong; Ilaria Bonoldi; Matilda Azis; Jesus Perez; Matthew Broome; David J Lythgoe; James M Stone; Oliver D Howes; Declan G Murphy; Anthony A Grace; Paul Allen; Philip McGuire
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

5.  Prefrontal GABA levels, hippocampal resting perfusion and the risk of psychosis.

Authors:  Gemma Modinos; Fatma Şimşek; Matilda Azis; Matthijs Bossong; Ilaria Bonoldi; Carly Samson; Beverly Quinn; Jesus Perez; Matthew R Broome; Fernando Zelaya; David J Lythgoe; Oliver D Howes; James M Stone; Anthony A Grace; Paul Allen; Philip McGuire
Journal:  Neuropsychopharmacology       Date:  2018-01-30       Impact factor: 7.853

6.  Baseline measures of cerebral glutamate and GABA levels in individuals at ultrahigh risk for psychosis: Implications for clinical outcome after 12 months.

Authors:  C Wenneberg; B Y Glenthøj; L B Glenthøj; B Fagerlund; K Krakauer; T D Kristensen; C Hjorthøj; R A E Edden; B V Broberg; K B Bojesen; E Rostrup; M Nordentoft
Journal:  Eur Psychiatry       Date:  2020-08-07       Impact factor: 5.361

7.  Reduced cortical GABA and glutamate in high schizotypy.

Authors:  Petya Kozhuharova; Andreea O Diaconescu; Paul Allen
Journal:  Psychopharmacology (Berl)       Date:  2021-06-19       Impact factor: 4.530
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.